Overview

GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma

Status:
RECRUITING

Trial end date:
2029-02-28

Target enrollment:

Participant gender:

Summary

Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.

Phase:

PHASE2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

AbbVie
Eli Lilly and Company
Genentech, Inc.

Treatments:

pirtobrutinib
Rituximab
venetoclax